CL2023001913A1 - Compuestos y métodos para modular el fxr. - Google Patents

Compuestos y métodos para modular el fxr.

Info

Publication number
CL2023001913A1
CL2023001913A1 CL2023001913A CL2023001913A CL2023001913A1 CL 2023001913 A1 CL2023001913 A1 CL 2023001913A1 CL 2023001913 A CL2023001913 A CL 2023001913A CL 2023001913 A CL2023001913 A CL 2023001913A CL 2023001913 A1 CL2023001913 A1 CL 2023001913A1
Authority
CL
Chile
Prior art keywords
compounds
methods
modulating fxr
fxr
modulating
Prior art date
Application number
CL2023001913A
Other languages
English (en)
Inventor
Xu Yingzi
KLUCHER Kevin
Romero F Anthony
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of CL2023001913A1 publication Critical patent/CL2023001913A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Disclosed herein are compounds that can be used as Farnesoid X Receptor (FXR) agonists, compositions containing these compounds and methods of use thereof.
CL2023001913A 2020-12-30 2023-06-28 Compuestos y métodos para modular el fxr. CL2023001913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063132363P 2020-12-30 2020-12-30

Publications (1)

Publication Number Publication Date
CL2023001913A1 true CL2023001913A1 (es) 2024-02-09

Family

ID=82258672

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001913A CL2023001913A1 (es) 2020-12-30 2023-06-28 Compuestos y métodos para modular el fxr.

Country Status (13)

Country Link
US (1) US20240116912A1 (es)
EP (1) EP4271377A1 (es)
JP (1) JP2024501700A (es)
KR (1) KR20230142478A (es)
CN (1) CN116887827A (es)
AU (1) AU2021413366A1 (es)
CA (1) CA3207069A1 (es)
CL (1) CL2023001913A1 (es)
CO (1) CO2023009817A2 (es)
IL (1) IL304121A (es)
MX (1) MX2023007870A (es)
PE (1) PE20240118A1 (es)
WO (1) WO2022147448A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7450951B2 (ja) * 2022-02-17 2024-03-18 カスケード ファーマシューティカルズ、インコーポレーテッド 新型ｆｘｒ小分子作動剤の製造およびその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360464A (en) * 1969-11-28 1982-11-23 Teikoku Hormone Mfg. Co. Ltd. Process for production of 1-aryloxy-aminopropane derivatives
CN106946867B (zh) * 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
US10080742B2 (en) * 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
MA46052A (fr) * 2016-08-23 2021-03-17 Ardelyx Inc Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
JP7398605B2 (ja) * 2019-04-19 2023-12-15 シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ Ｆｘｒ小分子アゴニストとその調製方法および用途

Also Published As

Publication number Publication date
JP2024501700A (ja) 2024-01-15
PE20240118A1 (es) 2024-01-22
US20240116912A1 (en) 2024-04-11
CA3207069A1 (en) 2022-07-07
MX2023007870A (es) 2023-11-09
EP4271377A1 (en) 2023-11-08
IL304121A (en) 2023-09-01
WO2022147448A1 (en) 2022-07-07
KR20230142478A (ko) 2023-10-11
CN116887827A (zh) 2023-10-13
AU2021413366A1 (en) 2023-08-17
CO2023009817A2 (es) 2023-09-08

Similar Documents

Publication Publication Date Title
EA202190726A1 (ru) Индольные ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение
CO2022010098A2 (es) Inhibidores de proteínas kras mutantes
EA201891344A1 (ru) Новые агонисты рецептора апелина и способы применения
EA202091186A1 (ru) ИНГИБИТОРЫ KRas G12C
PH12018501656A1 (en) Methods for using fxr agonists
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
BR112018071184A2 (pt) inibidores do receptor de activina tipo quinase
CL2023001913A1 (es) Compuestos y métodos para modular el fxr.
EA201891336A1 (ru) Гетероарилгидроксипиримидиноны в качестве агонистов рецептора apj
EA201892123A1 (ru) 6-гидрокси-4-оксо-1,4-дигидропиримидин-5-карбоксамиды в качестве агонистов apj
EA202092975A1 (ru) Селективные супрессоры рецептора эстрогена
NZ729618A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
MX2022014007A (es) Compuestos como inhibidores de bcl-2.
PH12019502326A1 (en) An isoxazole derivatives as nuclear receptor agonists and used thereof
MX2021014455A (es) Inhibidores de proteina cinasas dependientes de adn.
BR112018012177A2 (pt) ?moduladores de hidantação de canais kv 3?
EA201990159A1 (ru) Биарилметильные гетероциклы
EA202192867A1 (ru) Составы с пролонгированным высвобождением
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
EA202193334A1 (ru) Фармацевтические композиции, содержащие агонист fxr и фибрат, для применения при лечении холестатического заболевания печени
EA202191342A1 (ru) Модуляторы экспрессии irf5
MX2023003973A (es) Degradadores de transductores de señales y activadores de la transcripción (stat) y usos de los mismos.
MX2022011437A (es) Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
BR112016026725A8 (pt) compostos derivados de aminoéster, composição farmacêutica e seu uso
AU2020235128A8 (en) Transparent or semitransparent inverse microlatices of polyacrylamide as oil emulsion drift reducing agent